Literature DB >> 20394674

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009).

Izumi Namiki1, Shuhei Nishiguchi, Keisuke Hino, Fumitaka Suzuki, Hiromitsu Kumada, Yoshihito Itoh, Yusuhiro Asahina, Akihiro Tamori, Naoki Hiramatsu, Norio Hayashi, Masatoshi Kudo.   

Abstract

The consensus meeting for the diagnosis, management and treatment for hepatitis C was held in 45(th) annual meeting for the Japan Society of Hepatology (JSH) in June 2009 where the recommendations and informative statements were discussed including organizers and presenters. The Several important informative statements and recommendations have been shown. This was the fourth JSH consensus meeting of hepatitis C, however, the recommendations have not been published in English previously. Thus, this is the first report of JSH consensus of hepatitis C. The rate of development of hepatocellular carcinoma (HCC) in HCV-infected patients in Japan is higher than in the USA, because the average age of the HCV-infected patients is greater and there are more patients with severe fibrosis of the liver than in the USA. In Japan, more than 60% of HCV-infected patients are genotype 1b infection, and they show lower response to perinterferon and ribavirin combination treatment. To improve the response rate is also an important issue in our country. To establish the original recommendations and informative statements to prevent the development of HCC is a very important issue in Japan.

Entities:  

Year:  2010        PMID: 20394674     DOI: 10.1111/j.1872-034X.2010.00642.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  12 in total

1.  Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Authors:  Shiho Miyase; Katsuki Haraoka; Yoshihiro Ouchida; Yuko Morishita; Shigetoshi Fujiyama
Journal:  J Gastroenterol       Date:  2012-03-02       Impact factor: 7.527

2.  Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Shuya Matsuda; Masaru Muraoka; Yutaka Yasui; Shoko Suzuki; Takanori Hosokawa; Ken Ueda; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Yasuhiro Asahina; Namiki Izumi
Journal:  J Gastroenterol       Date:  2013-12-15       Impact factor: 7.527

3.  Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.

Authors:  Hideki Fujii; Takeshi Nishimura; Atsushi Umemura; Taichiro Nishikawa; Kanji Yamaguchi; Michihisa Moriguchi; Yoshio Sumida; Hironori Mitsuyoshi; Chihiro Yokomizo; Saiyu Tanaka; Hiroki Ishikawa; Kenichi Nishioji; Hiroyuki Kimura; Shiro Takami; Yasuyuki Nagao; Takayuki Takeuchi; Toshihide Shima; Yoshihiko Sawa; Masahito Minami; Kohichiroh Yasui; Yoshito Itoh
Journal:  World J Hepatol       Date:  2015-12-08

Review 4.  Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance.

Authors:  Katsuhisa Nakatsuka; Masanori Atsukawa; Masumi Shimizu; Hidemi Takahashi; Chiaki Kawamoto
Journal:  World J Hepatol       Date:  2015-11-08

5.  Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.

Authors:  Namiki Izumi; Yasuhiro Asahina; Masayuki Kurosaki; Gotaro Yamada; Tsutomu Kawai; Eiji Kajiwara; Yukishige Okamura; Takayuki Takeuchi; Osamu Yokosuka; Kazuya Kariyama; Joji Toyoda; Mie Inao; Eiji Tanaka; Hisataka Moriwaki; Hiroshi Adachi; Shinji Katsushima; Masatoshi Kudo; Kouichi Takaguchi; Yoichi Hiasa; Kazuaki Chayama; Hiroshi Yatsuhashi; Makoto Oketani; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2012-08-09       Impact factor: 7.527

6.  Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.

Authors:  Kazuyuki Imakiire; Hirofumi Uto; Yuko Sato; Fumisato Sasaki; Seiichi Mawatari; Akio Ido; Kazuya Shimoda; Katsuhiro Hayashi; Sherri O Stuver; Yoshito Ito; Takeshi Okanoue; Hirohito Tsubouchi
Journal:  Mol Med Rep       Date:  2012-05-21       Impact factor: 2.952

7.  Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.

Authors:  Namiki Izumi; Yasuhiro Asahina; Masayuki Kurosaki
Journal:  Hepat Res Treat       Date:  2010-09-05

8.  Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study.

Authors:  Naohiko Masaki; Yoko Yamagiwa; Takuro Shimbo; Kazumoto Murata; Masaaki Korenaga; Tatsuya Kanto; Masashi Mizokami
Journal:  BMC Public Health       Date:  2015-06-19       Impact factor: 3.295

Review 9.  Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.

Authors:  Jayne Smith-Palmer; Karin Cerri; William Valentine
Journal:  BMC Infect Dis       Date:  2015-01-17       Impact factor: 3.090

10.  Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.

Authors:  Naohiko Masaki; Masaya Sugiyama; Noritomo Shimada; Yasuhito Tanaka; Makoto Nakamuta; Namiki Izumi; Sumio Watanabe; Akihito Tsubota; Masafumi Komatsu; Tsutomu Masaki; Nobuyuki Enomoto; Masashi Yoneda; Kazumoto Murata; Kiyoaki Ito; Kazuhiko Koike; Masashi Mizokami
Journal:  J Gastroenterol Hepatol       Date:  2014-12       Impact factor: 4.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.